MedWatch

Orphazyme board on CEO changes: She had an old-fashioned management style

Kim Stratton preferred leaving the role of CEO at Orphazyme over fulfilling the board of directors' requirements that she include the board and executive team in her decisions, says Vice Chair Bo Jesper Hansen. "Some would call her management style very American, but I think it's more that; it's old-fashioned," he says.

Kim Stratton, former CEO, Orphazyme

On Thursday, the biotech firm Orphazyme announced that the CEO Kim Stratton would no longer be working at the firm after serving for just one year and two months, but she was not fired.

Instead, the now-former CEO made this choice in a dialog with the board of directors, as the latter was displeased with the management style of the Australian CEO, explains Orphazyme Vice Chair Bo Jesper Hansen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs